Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Antibody-drug Conjugate
100%
Management Strategies
100%
Ocular Adverse Events
100%
Dose Reduction
18%
Dose Adjustment
18%
Dose Delay
18%
High-level Expression
9%
English Language
9%
Clinical Outcomes
9%
Cancer Cells
9%
PubMed
9%
Literature Search
9%
Patient Outcomes
9%
Expert Opinion
9%
Multidisciplinary Approach
9%
Therapeutic Implications
9%
Current Guidelines
9%
Cancer Drugs
9%
Treatment Discontinuation
9%
Systemic Exposure
9%
Topical Steroids
9%
Target Antigen
9%
Impact Treatment
9%
Delay Reduction
9%
Corneal Fluorescein Staining
9%
Google Scholar
9%
Artificial Tears
9%
Recommendations for Practice
9%
Blurred Vision
9%
Off-target Effects
9%
Conjunctivitis
9%
Search Terms
9%
Treatment Administration
9%
Cytotoxic Payload
9%
Foreign Body Sensation
9%
Expert Recommendation
9%
Fast-growing
9%
Antibody Binding
9%
Vasoconstrictor
9%
Medicine and Dentistry
Malignant Neoplasm
100%
Adverse Event
100%
Antibody-Drug Conjugate
100%
English (Language)
9%
Cancer Cell
9%
Antigen
9%
Foreign Body
9%
Fluorescein
9%
Topical Corticosteroid
9%
Drug Dose Reduction
9%
Sensation
9%
Antigen Binding
9%
Artificial Tear
9%
Corneal Staining
9%
Conjunctivitis
9%
Vasoconstrictor
9%
Blurred Vision
9%
Pharmacology, Toxicology and Pharmaceutical Science
Malignant Neoplasm
100%
Adverse Event
100%
Antibody Drug Conjugate
100%
Foreign Body
9%
Topical Corticosteroid
9%
Antigen
9%
Artificial Tear
9%
Fluorescein
9%
Blurred Vision
9%